GIOTRIF® :
The 1st choice in 1st-line
Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
demonstrated in 3 large trials in 1st-line EGFR M+ NSCLC1-4*
Dosing and administration
References & Footnote:
1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
2. Wu YL et al. Lancet Oncol. 2014;15(2):213-22.
3. Yang JC et al. Lancet Oncol. 2015;16(2):141-51.
4. Park K et al. Lancet Oncol 2016;17(5):577–89.
EGFR M+=epidermal growth factor receptor mutation positive; NSCLC=non-small cell lung cancer; PFS=progression-free survival; OS=overall survival.
* LUX-Lung 3 (vs pemetrexed/cisplatin) and LUX-Lung 6 (vs gemcitabine/cisplatin): superior PFS (primary endpoint) and superior OS in Del19 subgroup (secondary endpoint); LUX-Lung 7 (vs gefitinib): superior PFS (primary endpoint).
PC-MY-100578
Production date: Oct 2019
Production date: Oct 2019